Buchang Pharmaceutical: Company Receives Drug Registration Certificate for Tomoxetine Hydrochloride Oral Solution

36Kr reports that Buchang Pharmaceutical announced the company recently received the 'Drug Registration Certificate' for Tomoxetine Hydrochloride Oral Solution, approved and issued by the National Medical Products Administration. The drug is indicated for the treatment of attention deficit/hyperactivity disorder (ADHD) in children and adolescents aged 6 years and older.